Go Deep
Theralase Technologies Inc.
Theralase Technologies Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 16,667 | -20.0 | 9.08 | 0.02 | 13.59 |
| Oct 2026 | 16,667 | -20.0 | 9.08 | 0.02 | 13.53 |
Theralase Technologies Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 164,293.0 | 132,634.0 | 225,895.0 | 279,640.0 |
| Net Profit | -1,062,141.0 | -1,031,785.0 | -685,672.0 | -1,011,911.0 |
| EPS | -0.0 | -0.0 | — | -0.0 |
Theralase Technologies Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 816,468.0 | 1,033,431.0 | 1,070,307.0 | 1,138,569.0 | — |
| Net Profit | -4,120,817.0 | -4,256,114.0 | -4,570,879.0 | -5,235,302.0 | — |
| EPS | -0.0 | -0.0 | -0.0 | -0.0 | — |
Theralase Technologies Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 3,494,628.0 | 3,246,949.0 | 3,276,806.0 | 4,160,904.0 | — |
| Total Liabilities | 1,716,812.0 | 1,179,501.0 | 1,371,364.0 | 1,068,336.0 | — |
| Total Equity | 1,777,816.0 | 2,067,448.0 | 1,905,442.0 | 3,092,568.0 | — |
Owes vs Owns
Theralase Technologies Inc. owed C$0.16 for every C$1 it owned in Jun 2026, down from C$0.26 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.16× | 0.49× | 0.36× | 0.42× | 0.26× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Theralase Technologies Inc. Assets & Liabilities Breakdown (CAD millions)
What it owns — Dec 2025
Cash & short-term investments 5.2%Receivables 34.3%Inventory 14.5%Fixed assets (tangible) 12.8%Other assets 33.2%
How it's funded — Dec 2025
Short-term debt 7.3%Long-term debt 2.7%Payables 22.5%Other liabilities 16.6%Shareholders' equity 50.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 0.2 | 0.3 | 0.0 | 1.5 |
| Receivables | 1.2 | 0.7 | 0.6 | 0.4 |
| Inventory | 0.5 | 0.5 | 0.7 | 0.5 |
| Fixed assets (tangible) | 0.4 | 0.6 | 0.9 | 1.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.2 | 1.1 | 1.1 | 0.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.3 | 0.1 | 0.1 | 0.1 |
| Long-term debt | 0.1 | 0.2 | 0.3 | 0.4 |
| Payables | 0.8 | 0.4 | 0.7 | 0.3 |
| Other liabilities | 0.6 | 0.5 | 0.3 | 0.3 |
| Shareholders' equity | 1.8 | 2.1 | 1.9 | 3.1 |
| Net tangible assets | 1.8 | 2.1 | 1.9 | 3.1 |
Theralase Technologies Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -3,285,750.0 | -3,350,201.0 | -4,072,806.0 | -5,102,894.0 | — |
| Investing Activities | -48,935.0 | -19,967.0 | -37,265.0 | -70,412.0 | — |
| Financing Activities | 3,248,842.0 | 3,595,014.0 | 2,645,364.0 | 2,990,264.0 | — |